Fatigue · people with ALS/MND
1 finding from 1 review
Adverse events · people with ALS/MND
1 finding from 1 review
Fatigue · people with ALS/MND
1 finding from 1 review
Adverse events · people with ALS/MND
1 finding from 1 review
Survival · people with ALS
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · people with ALS
1 finding from 1 review
Quality of Life: SF‐36 (physical component) · people with ALS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (SAQLI) · people with ALS
1 finding from 1 review
Adverse events (not reported) · people with ALS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Survival at 1 year Estimated survival at 1 year based on trials of 6 and 9 months' duration · people with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline in MVIC Expressed as arm megascore1 · people with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline of % predicted FVC · people with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline (per month) of functional rating scale (over a period of 9 months) Measured by ALSFRS‐R · people with ALS/MND
1 finding from 1 review
Intervention not reported
Health‐related quality of life Short Form 12 Health Survey (SF‐12) · people with ALS/MND
1 finding from 1 review
Intervention not reported
Adverse events · people with ALS/MND
1 finding from 1 review
Intervention not reported
Mortality or tracheostomy at 12 months (pooled hazard ratio)(riluzole 100 mg) · patients with ALS/MND
The intervention showed no clear difference in mortality or tracheostomy at 12 months (pooled hazard… (high certainty).
1 finding from 1 review
Intervention not reported
Per cent mortality at 12 months (riluzole 100 mg) · patients with ALS/MND
The intervention leads to lower per cent mortality at 12 months (riluzole 100 mg) (high certainty).
1 finding from 1 review
Intervention not reported
Rate of decline of Norris Scale ‐ Norris Limb (riluzole 100 mg) · patients with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline of Norris Scale ‐ Norris Bulbar (riluzole 100 mg) · patients with ALS/MND
1 finding from 1 review
Intervention not reported
Adverse event: nausea · patients with ALS/MND
The intervention leads to higher adverse event: nausea (high certainty).
1 finding from 1 review